PharmaCyte Biotech Appoints New Chief Medical Officer

- July 26th, 2017

PharmaCyte Biotech appointed Dr. Linda Sher as chief medical officer.

PharmaCyte Biotech (OTCQB:PMCB) appointed Dr. Linda Sher as chief medical officer.
As quoted in the press release:

Dr. Sher is a Professor of Clinical Surgery and Director of Clinical Research in the Division of Hepatobiliary and Pancreatic Surgery and Abdominal Organ Transplantation at the University of Southern California’s (USC) Keck School of Medicine. Dr. Sher is also the Chief of the Division of Clinical Research for the Department of Surgery where she oversees the implementation and conduct of clinical trials for the entire department, averaging between 50 and 70 studies at all times. She is also the Vice Chair of the USC Institutional Review Board.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are extremely fortunate to have someone with Dr. Sher’s credentials and experience in such a critically important position as our Chief Medical Officer. Dr. Sher will be responsible for the strategy, direction and execution of PharmaCyte’s clinical development plans, an essential position for a biotech company about to embark upon a pivotal trial in pancreatic cancer.
“Not only will Dr. Sher be a key member of the senior management team, she will oversee our entire clinical research program. Dr. Sher has been the Principal or Co-Principal Investigator on more than 50 clinical trials. This experience is invaluable to PharmaCyte. Dr. Sher is expected to contribute considerably to our success as a biotech company and, most importantly, to a successful pivotal trial in pancreatic cancer.”

Click here to read the full press release.


Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply